Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $29.14.
A number of equities analysts have recently commented on BCYC shares. B. Riley reduced their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Needham & Company LLC restated a “buy” rating and set a $30.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a research note on Friday, November 1st. HC Wainwright reiterated a “buy” rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday. Finally, JMP Securities cut their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th.
View Our Latest Stock Analysis on Bicycle Therapeutics
Insiders Place Their Bets
In related news, Director Bros. Advisors Lp Baker acquired 985,397 shares of the business’s stock in a transaction on Friday, December 13th. The stock was purchased at an average cost of $13.76 per share, for a total transaction of $13,559,062.72. Following the completion of the transaction, the director now directly owns 9,537,643 shares of the company’s stock, valued at approximately $131,237,967.68. The trade was a 11.52 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Travis Alvin Thompson sold 2,686 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $15.00, for a total transaction of $40,290.00. Following the sale, the chief accounting officer now owns 32,146 shares of the company’s stock, valued at $482,190. This trade represents a 7.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,677 shares of company stock worth $392,413 over the last three months. Insiders own 8.50% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. increased its holdings in shares of Bicycle Therapeutics by 406.2% during the fourth quarter. Point72 Asset Management L.P. now owns 4,554,900 shares of the company’s stock worth $63,769,000 after purchasing an additional 3,655,101 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Bicycle Therapeutics by 43.3% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 80,236 shares of the company’s stock worth $1,123,000 after purchasing an additional 24,260 shares during the period. Millennium Management LLC bought a new position in shares of Bicycle Therapeutics during the fourth quarter worth approximately $2,475,000. Fcpm Iii Services B.V. increased its holdings in shares of Bicycle Therapeutics by 47.5% during the fourth quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company’s stock worth $48,333,000 after purchasing an additional 1,112,369 shares during the period. Finally, Caption Management LLC bought a new position in shares of Bicycle Therapeutics during the fourth quarter worth approximately $2,283,000. 86.15% of the stock is owned by institutional investors.
Bicycle Therapeutics Price Performance
Bicycle Therapeutics stock opened at $10.97 on Friday. The firm has a 50-day moving average of $13.27 and a 200-day moving average of $19.40. Bicycle Therapeutics has a one year low of $10.81 and a one year high of $28.67. The company has a market cap of $757.43 million, a price-to-earnings ratio of -3.33 and a beta of 0.93.
Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.47 million. During the same period in the prior year, the business posted ($1.16) EPS. The company’s quarterly revenue was down 30.2% on a year-over-year basis. As a group, sell-side analysts expect that Bicycle Therapeutics will post -3.06 earnings per share for the current year.
Bicycle Therapeutics Company Profile
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Further Reading
Receive News & Ratings for Bicycle Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bicycle Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
